KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In Process
Ratios

CRISPR Therapeutics AG (CRSP) Other Gross PP&E Adjustments (2016 - 2025)

CRISPR Therapeutics AG's Other Gross PP&E Adjustments history spans 11 years, with the latest figure at $56.4 million for Q4 2025.

  • For Q4 2025, Other Gross PP&E Adjustments rose 33.12% year-over-year to $56.4 million; the TTM value through Dec 2025 reached $56.4 million, up 33.12%, while the annual FY2025 figure was $56.4 million, 33.12% up from the prior year.
  • Other Gross PP&E Adjustments for Q4 2025 was $56.4 million at CRISPR Therapeutics AG, down from $68.8 million in the prior quarter.
  • Across five years, Other Gross PP&E Adjustments topped out at $68.8 million in Q3 2025 and bottomed at -$79.5 million in Q2 2021.
  • The 5-year median for Other Gross PP&E Adjustments is $44.4 million (2023), against an average of $32.9 million.
  • The largest annual shift saw Other Gross PP&E Adjustments plummeted 919.37% in 2021 before it skyrocketed 692.71% in 2022.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at -$3.8 million in 2021, then surged by 692.71% to $22.5 million in 2022, then surged by 117.09% to $48.9 million in 2023, then dropped by 13.34% to $42.4 million in 2024, then soared by 33.12% to $56.4 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Other Gross PP&E Adjustments are $56.4 million (Q4 2025), $68.8 million (Q3 2025), and $65.3 million (Q2 2025).